Orthocell says October was its best U.S. sales month for Remplir since launch
Orthocell reported 92 Remplir units sold in the U.S. in October 2026 for AU$279,000, an 84% rise on its Q1 FY27 monthly average of 50 units.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Australian company Orthocell reported that its collagen nerve wrap Remplir™ sold 92 units in the U.S. in October 2026, bringing in AU$279,000, according to a publication carried by TradingView. That is 84% above the average monthly volume of 50 units in the first quarter of fiscal 2027 and the strongest month of U.S. sales since the product launched there.
The company links the growth to wider surgeon use, repeat orders, a larger number of active distributor representatives and access to more hospitals. Chairman John Van Der Wielen said the board is expanding manufacturing capacity in expectation of higher demand.
why it matters
This is an operational update from a small medical technology company, so its effect on the broader market is limited. Revenue remains modest, and medical devices typically take time to reach steady volumes. Investors will look to coming quarterly results for confirmation, and the next scheduled event is the annual general meeting on 6 November 2026.
tags
instruments
sources
- Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch — TradingView, 2 November 2026 at 00:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗